公开(公告)号：US20230357135A1

公开(公告)日：2023-11-09

申请号：US18009670

申请日：2021-06-11

Applicant: Paratek Pharmaceuticals, Inc.

Inventor： Tadeusz Warchol ,  Sean M. Johnston

IPC: C07C237/26

CPC classification number: C07C237/26 ,  C07B2200/13 ,  C07C2603/46

Abstract: The present invention provides omadacycline crystalline freebase and methods of synthesis thereof. The present invention also provides pharmaceutical compositions comprising omadacycline crystalline freebase and methods of use thereof for treating bacterial infections. The present invention also provides methods of purifying crude omadacycline freebase that comprise crystallization to produce crystalline omadacycline freebase. The omadacycline crystalline freebase may also be used to prepare salts of omadacycline, e.g., a tosylate salt.

公开(公告)号：US20210121483A1

公开(公告)日：2021-04-29

申请号：US17141763

申请日：2021-01-05

Applicant: Paratek Pharmaceuticals, Inc.

Inventor： Sean M. Johnston ,  Robert D. Arbeit ,  Thomas J. Bigger ,  Dennis P. Molnar ,  S. Ken Tanaka

IPC: A61K31/65 ,  A61K31/165

Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, Enterococcus, or combinations thereof.

公开(公告)号：US20180153908A1

公开(公告)日：2018-06-07

申请号：US15798573

申请日：2017-10-31

Applicant: Paratek Pharmaceuticals, Inc.

Inventor： Evangelos L. Tzanis ,  Paul McGovern

IPC: A61K31/65 ,  A61K9/00 ,  A61P11/00

CPC classification number: A61K31/65 ,  A61K9/0019 ,  A61K9/0053 ,  A61P11/00 ,  A61P31/04 ,  Y02A50/473 ,  Y02A50/478

Abstract: The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.

公开(公告)号：US20180078534A1

公开(公告)日：2018-03-22

申请号：US15474948

申请日：2017-03-30

Applicant: PARATEK PHARMACEUTICALS, INC.

Inventor： Nikhilesh N. Singh ,  Sathasivan I. Pather

IPC: A61K31/437 ,  A61K31/4745 ,  A61K9/20 ,  A61K9/00 ,  A61K9/02 ,  A61K9/68

CPC classification number: A61K31/437 ,  A61K9/0056 ,  A61K9/0058 ,  A61K9/006 ,  A61K9/02 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/4745

Abstract: The present invention provides liquid dosage forms for treating narcolepsy. The liquid dosage form includes zolpidem or a pharmaceutically acceptable salt thereof, a carbonate salt, a citrate salt, and a phosphate salt. The present invention also provides methods for treating somnambulism. The methods include administering an emulsion that includes zolpidem, a bicarbonate salt, a metal oxide, and a borate salt.

公开(公告)号：US20170158616A1

公开(公告)日：2017-06-08

申请号：US15209178

申请日：2016-07-13

Applicant: Paratek Pharmaceuticals, Inc.

Inventor： Sean M. Johnston ,  Tadeusz Warchol

IPC: C07C231/12 ,  C07C231/24

CPC classification number: C07C231/12 ,  C07C231/24 ,  C07C2603/46 ,  C07C237/26

Abstract: Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described.

公开(公告)号：US09533943B2

公开(公告)日：2017-01-03

申请号：US14281357

申请日：2014-05-19

Applicant: Paratek Pharmaceuticals, Inc.

Inventor： Todd Bowser ,  Mark Grier

IPC: A61K31/65 ,  C07C237/26 ,  C07C237/48 ,  C07C271/22 ,  C07C271/54 ,  C07C275/28 ,  C07C275/30

CPC classification number: C07C237/48 ,  A61K31/65 ,  C07C237/26 ,  C07C271/22 ,  C07C271/54 ,  C07C275/28 ,  C07C275/30 ,  C07C2601/02 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2603/46

Abstract: The present invention pertains, at least in part, to novel substituted etracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.

Abstract translation: 本发明至少部分地涉及新的取代的依卡环素化合物。 这些四环素化合物可用于治疗许多四环素化合物反应状态，例如细菌感染和肿瘤，以及四环素化合物的其它已知应用，例如阻断四环素外排和调节基因表达。

公开(公告)号：US09522872B2

公开(公告)日：2016-12-20

申请号：US12217709

申请日：2008-07-07

Applicant: Farzaneh Seyedi ,  Tadeusz Warchol ,  Mark Grier

Inventor： Farzaneh Seyedi ,  Tadeusz Warchol ,  Mark Grier

IPC: C07C237/12 ,  C07C231/12

CPC classification number: C07C231/12 ,  C07C2603/44 ,  C07C237/26

Abstract: Methods of synthesizing substituted tetracycline compounds are provided.

公开(公告)号：US09434680B2

公开(公告)日：2016-09-06

申请号：US12110627

申请日：2008-04-28

Applicant: Sean Johnston ,  Tadeusz Warchol

Inventor： Sean Johnston ,  Tadeusz Warchol

IPC: C07C231/24 ,  C07C231/12

CPC classification number: C07C231/12 ,  C07C231/24 ,  C07C2603/46 ,  C07C237/26

Abstract: Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described.

公开(公告)号：US09365500B2

公开(公告)日：2016-06-14

申请号：US14318031

申请日：2014-06-27

Applicant: Paratek Pharmaceuticals, Inc.

Inventor： Mark L. Nelson ,  Roger Frechette ,  Mohamed Y. Ismail ,  Laura Honeyman ,  Todd Bowser ,  Beena Bhatia

IPC: C07C237/26 ,  C07D317/66

CPC classification number: C07C237/26 ,  C07D317/66

Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

公开(公告)号：US09278911B2

公开(公告)日：2016-03-08

申请号：US14176923

申请日：2014-02-10

Applicant: Paratek Pharmaceuticals, Inc.

Inventor： Mark L. Nelson ,  Kwasi Ohemeng

IPC: A61K31/65 ,  C07C237/26 ,  C07C235/70 ,  C07C251/48 ,  C07C255/41 ,  C07C271/22 ,  C07C271/54 ,  C07C271/58 ,  C07C275/42 ,  C07C275/54 ,  C07C279/18 ,  C07C311/06 ,  C07C311/08 ,  C07C333/08 ,  C07C335/22 ,  C07C381/10 ,  C07D295/155 ,  C07D295/185 ,  C07D317/60 ,  C07F9/24 ,  C07F9/40

CPC classification number: A61K31/65 ,  C07C235/70 ,  C07C237/26 ,  C07C251/48 ,  C07C255/41 ,  C07C271/22 ,  C07C271/54 ,  C07C271/58 ,  C07C275/42 ,  C07C275/54 ,  C07C279/18 ,  C07C311/06 ,  C07C311/08 ,  C07C333/08 ,  C07C335/22 ,  C07C381/10 ,  C07C2601/08 ,  C07C2601/10 ,  C07C2601/16 ,  C07C2603/46 ,  C07D295/155 ,  C07D295/185 ,  C07D317/60 ,  C07F9/2475 ,  C07F9/4006

Abstract: The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.